Processa Pharmaceuticals, Inc. (PCSA) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing "Next Generation Chemotherapy" (NGC) drugs designed to improve the safety and efficacy of existing FDA-approved oncology treatments. The company has no product revenue and relies on equity financing to fund operations. A 1-for-20 reverse stock split was effected on January 22, 2024.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,384,703) | $(2,081,951) | $(9,121,410) | $(8,716,589) |
| Net Loss Per Share (Basic/Diluted) | $(1.03) | $(1.54) | $(3.13) | $(6.81) |
| Cash and Cash Equivalents (End of Period) | $2,891,464 | $6,860,672 | $2,891,464 | $6,860,672 |
| Net Cash Used in Operating Activities (YTD) | $(8,997,321) | $(5,939,478) | $(8,997,321) | $(5,939,478) |
| Net Cash Provided by Financing Activities (YTD) | $7,185,832 | $6,299,331 | $7,185,832 | $6,299,331 |
| Total Assets | $4,942,152 | $5,786,643 | $4,942,152 | $5,786,643 |
| Accumulated Deficit | $(84,490,491) | $(72,964,150) | $(84,490,491) | $(72,964,150) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Research and Development (R&D) expenses increased by approximately $1.1 million in Q3 2024 compared to Q3 2023, driven by costs associated with the Phase 1B trial for NGC-Cap and the initiation of the Phase 2 trial. General and Administrative (G&A) expenses increased by approximately $121,000 due to higher stock-based compensation and professional fees.
- Cash Position: Cash and cash equivalents decreased by approximately $1.8 million during the nine months ended September 30, 2024, primarily due to increased operating cash burn offset by net proceeds from equity financings.
- Financing Activity: The company raised approximately $6.3 million in net proceeds from a public offering in January 2024 and approximately $931,000 from an "at-the-market" (ATM) offering in July 2024.
- Share Count: Outstanding shares increased significantly due to the January 2024 offering and subsequent ATM sales, rising from 1,286,000 at year-end 2023 to 3,266,944 as of September 30, 2024.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management explicitly states that current cash ($2.9 million) is not sufficient to fund operations for the next twelve months. Substantial doubt exists regarding the company's ability to continue as a going concern without additional funding via equity, debt, or strategic transactions.
- Clinical Progress: The company received FDA IND clearance for its Phase 2 trial of NGC-Cap in breast cancer on July 24, 2024. The first patient was dosed on October 2, 2024. The company anticipates R&D costs will increase as this trial progresses.
- Legal Proceedings: The company is in litigation with Elion Oncology, Inc. regarding the termination of a license agreement for NGC-Cap. Elion alleged a breach of contract; Processa disputes this and has filed a complaint seeking damages and declaratory judgment.
- License Milestones: The company is in discussions with Ocuphire Pharma to extend diligence milestones for NGC-Gem, which were originally due in June 2024.
- Management Changes: Russell Skibsted was appointed Chief Financial Officer in July 2024.
Investor Verification Checklist
- Runway Analysis: Verify the specific timeline for the next funding round given the explicit "substantial doubt" regarding the ability to fund operations for 12 months.
- Legal Status: Monitor the status of the litigation with Elion Oncology, as a loss could jeopardize the rights to the lead asset, NGC-Cap.
- Dilution Risk: Assess the impact of potential future equity raises required to fund the Phase 2 trial, noting the existing ATM facility and warrant overhang.
- Clinical Milestones: Track enrollment and safety data from the newly initiated Phase 2 trial for NGC-Cap in breast cancer.
- License Compliance: Confirm the outcome of discussions with Ocuphire regarding the extension of NGC-Gem diligence milestones.